Peter Marks received his graduate degree in cell and molecular biology and his medical degree at New York University and completed Internal Medicine residency and Hematology/Medical Oncology training at Brigham and Women’s Hospital in Boston. He has worked in academic settings teaching and caring for patients and in industry on drug development. He joined the FDA in 2012 as Deputy Center Director for CBER and became Center Director in January 2016.

Kenneth A. Getz is the Deputy Director and a professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine, where he conducts research focusing on drug development management and operating strategies and tactics; protocol design practices; and global outsourcing, investigative site and patient recruitment practices and policies. He is also the chairman of CISCRP – a nonprofit organization that he founded to educate and raise public and patient awareness of the clinical research enterprise. A well-known speaker at conferences, symposia, universities, investor meetings and corporations, Ken has published extensively in peer-review journals, books and in the trade press and writes a bi-monthly column nominated for a Neal Award in Applied Clinical Trials. He holds a number of board appointments in the private and public sectors including WCG and ORA and serves on the editorial boards of Pharmaceutical Medicine and Therapeutic Innovation and Regulatory Science. Ken received an MBA from the J.L. Kellogg Graduate School of Management at Northwestern University and a bachelor’s degree, Phi Beta Kappa, from Brandeis University. Ken is the founder of CenterWatch, a leading publisher in the clinical trials industry.

Karen is currently PwC's US Health Industries Leader with more than two decades of experience in professional services spanning across Health Industries. As Health Industries leader, Karen leads a multi-disciplinary team of 6,000 and drives the overall strategic direction for the life sciences and health care practices, including consulting, audit, and tax services in the United States. She guides teams of professionals representing the health industry across the payer, provider, pharmaceutical, and life sciences sectors to reinvent wellness, solve disease, address pandemics and tackle health inequities. Prior to this role, Karen was the US Pharmaceutical and Life Sciences Leader specializing in pharmaceutical, life science, medical device and biotech. In that role, she led a team of more than 3,000 professionals in strategic development experience across strategy, operations, deals and technology delivering in organizational areas of commercial, R&D, supply chain and finance.

Michelle McMurry-Heath assumed the leadership of the Biotechnology Innovation Organization (BIO) as President and CEO on June 1, 2020. A medical doctor and molecular immunologist by training, Dr. McMurry-Heath becomes just the third chief executive to steward the world’s largest biotechnology advocacy group since BIO’s founding in 1993.
BIO represents 1,000 life sciences companies and organizations from 30 countries. The organization’s mission is to discover and deploy scientific breakthroughs that improve human heath, environmental stewardship, and sustainable agriculture.
The common thread in McMurry-Heath’s work across academia, government and industry has been her focus on broadening access to scientific progress so more patients from diverse backgrounds can benefit from cutting-edge innovation. Driven by her own past family experiences navigating clinical trials and funding uncertainties within the rare disease community, McMurry-Heath calls “the distribution of scientific progress the social justice issue of our age.”

Dr. Pang serves as Chief Medical Office for Vir, where he is responsible for overseeing the Company’s global clinical development portfolio. His career in industry has been dedicated to the development of novel therapies to address some of the world’s most challenging infectious diseases. Since joining the company in 2016, Dr. Pang has advanced numerous compounds through early- mid- and into late-stage clinical development, including the company’s lead SARS-CoV-2 candidate, VIR-7831, which moved into Phase 3 in October 2020.
Prior to joining Vir, Dr. Pang served as Chief Medical Officer of Riboscience LLC, a Roche-spinoff developing small molecule antivirals. Previously, during his four-year tenure as Program Lead at Gilead Sciences, Inc., Dr. Pang led a large matrix team to the successful worldwide approval of the first one-pill, once-a-day hepatitis C treatment.

Ana Céspedes, PhD, MBA, is Chief Operating Officer of IAVI, a global organization dedicated to developing globally affordable and accessible vaccines and antibodies for infectious and neglected diseases. This includes HIV, TB and COVID-19.
Within IAVI, Dr. Céspedes provides oversight and strategic direction in addressing the operational needs of the organization globally. She enables and maximizes coordination across the global senior leaders responsible of Access and Commercialization; Government Affairs; Communications; India & Africa operations; Legal, Strategy & Business Development; Finance; and, Human Resources.
Ana is a senior global leader with experience across Life Sciences organizations and business consulting. She has successfully built and executed growth and launch strategies focused on multi-customer models (physicians, payers, patients, policy makers), seamless cross-functional collaborations, 360-communication strategies, and implementation of digital technologies and platforms to maximize business outcomes and improve effectiveness.

Ben brings both biopharma expertise and diverse experience. For the past five and a half years, he was a senior manager in PwC’s Health Research Institute. He developed reports on various policy issues and business trends, particularly in the pharma and medtech sectors, provided research for clients and spoke at industry events. Previously, he was a journalist with Pharmaceutical Executive; Medical Marketing & Media, PRWeek and Direct Marketing News; and Ad-Fax Media.

Mene was appointed as Executive Vice-President, R&D BioPharmaceuticals in January 2019 and is responsible for BioPharmaceutical R&D from discovery through to late-stage development covering Cardiovascular, Renal, Metabolism, Respiratory, Inflammation, Autoimmune, Microbial Science and Neuroscience areas. Prior to this, he served as Executive Vice-President of AstraZeneca's IMED Biotech Unit and Global Business Development.
Since joining AstraZeneca in 2010, Mene has led the transformation of R&D productivity through the development and implementation of the "5R" framework resulting in a greater than four-fold increase in success rates compared to industry averages. In parallel, he has championed an open approach to working with academic and other external partners, changing the nature of academic-industry collaboration. Mene previously held senior R&D roles at Wyeth and GSK.
Mene also oversees the creation of AstraZeneca's new Global R&D Centre in Cambridge - a state of the art facility designed to stimulate collaborative scientific innovation and which will play an important role in the future success of the UK life science industry.

Dr Michael Devoy is the Executive Vice President for Medical Affairs and Pharmacovigilance for the Pharmaceuticals Division at Bayer AG. He is also the Chief Medical Officer of Bayer AG. Dr Devoy joined the former Schering AG in 2005 as Senior Vice President of Global Medical Development and was appointed to his current position in 2014.
Dr Devoy studied Medicine and Pharmacology at University College London and graduated with a Bachelor of Medicine/Bachelor of Surgery (MB, BS). He is a member of the Royal College of Physicians in London. He is also an elected member of the Board of Directors of the Drug Information Association (DIA).
Dr Devoy has extensive experience across Clinical Development and International Medical Affairs. His career in the pharmaceutical industry began when he joined Glaxo Group Research in Clinical Pharmacology.

Adrian van den Hoven joined Medicines for Europe as a Director General in September 2013. His priorities at Medicines for Europe are to stimulate competition in off-patent medicine markets, to foster market access for generic, biosimilar and value added medicines, to support policy measures for sustainable pricing, to promote high regulatory standards while ensuring that the associated costs can be integrated into market dynamics and to develop a coherent EU industrial strategy to support the long-term viability of the generic, biosimilar and value added medicines industries. Adrian is also the President of the European Medicines Verification Organisation (EMVO) for the implementation of serialisation against falsified medicines. Prior to joining Medicines for Europe, Adrian van den Hoven was Deputy-Director General of BUSINESSEUROPE where he was responsible for the International Relations department, covering trade negotiations and bilateral relations, and the Industry department, covering industrial, energy, environmental and research policy. He previously worked as an International Relations researcher and an adjunct professor in Italy (EUI), France (Nice) and Canada (Windsor). He obtained his doctorate in Political Science from the University of Nice, France in 2000.

James has over 20 years’ experience in the pharmaceutical industry, predominantly in the generics and biosimilar sector. James holds a bachelor's Degree of Chemical and Biochemical Engineering and a Doctor of Philosophy degree in Chemical Engineering, both from the University of Birmingham. James' pharma experience includes UK, Europe and Global management roles in commercial, business development and general management positions.
As Executive Vice President EMENA, James leads Accord's operations in the EMENA territory, with particular responsibility for developing and delivering the company's strategy to improve access to high quality affordable medicine within the region. James joined Accord in 2010 and over the last eight years has grown the company from a small base of less than 50 employees to over 1,400 people across over 25 different countries and a current annual revenue target of over three quarters of a billion dollars. Accord Healthcare is committed to further growth by attracting and retaining motivated people, empowered to bring to market an exceptional pipeline of generic, biosimilar and novel medicines.

Dr. Rainer Lichtenberger co-founded Atriva Therapeutics in 2015 together with a team of leading scientists in viral research and seasoned industry experts to specifically develop new host-targeting antiviral therapies against severe respiratory viral infections with a high unmet medical need. Atriva today is focused on developing treatments against influenza and COVID-19. Dr. Lichtenberger has worked in the biopharmaceutical industry for 30 years and has been a serial entrepreneur for the last 10+ years. He began his industry career at Merck KGaA, where he worked in a variety of positions for nearly 14 years, followed by executive positions with Merckle/ratiopharm. From there, he founded and/or led a variety of companies, including LBC Advisors, CEVEC Pharmaceuticals and Neuraxo Pharmaceuticals. He is a successful deal maker and has successfully grown a number of SMEs. Dr. Lichtenberger holds a PhD in Pharmaceutics from the University of Bonn and an executive MBA from the Ashridge Business School, UK.

Daniel has a decade of experience as an analyst in the biopharma industry, spanning roles in drug discovery, market analysis, competitive intelligence, and strategic consulting. He now develops and leads Informa Pharma Intelligence's thought leadership program, producing materials that help clients across a range of hot topics in the biopharma industry, most recently including COVID-19, immuno-oncology, tumor-agnostic drug development, artificial intelligence and M&A. As part of this, Daniel regularly participates in webinars, conferences and other speaking arrangements, and he is featured across leading publications such as Nature Reviews Drug Discovery, Scientific American, Scrip, In Vivo and Vice. Prior to joining Informa, Daniel worked as a medicinal chemist at the UK biotech company Summit Therapeutics and graduated with First Class Honours in Natural Sciences from the University of Bath.